ライフサイエンスコーパス: Merck

1 , Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

2 ssociated with higher levels of replication (Merck 035), but was not associated with virologic failur

3 ndinavir-zidovudine-lamivudine (ACTG 343 and Merck 035).

4 ected subjects enrolled in a clinical trial (Merck 039).

5 precolumn Chromolith Guard Cartridge RP-18e (Merck), 10x4.6mm, with a washing mobile phase (methanol:

6 f quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 years previously.

7 x (varicella virus vaccine live [Oka/Merck]; Merck), a live attenuated varicella vaccine, is indicate

8 University of New South Wales Australia, Merck, AbbVie, and the Foundation for AIDS Research.

9 li study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine

10 HDM sublingual immunotherapy tablet MK-8237 (Merck/ALK-Abello) using the Vienna Challenge Chamber.

11 s SLIT-tablet MK-7243 (2800 BAU/75 000 SQ-T, Merck/ALK-Abello) were pooled for post hoc analyses.

12 est datasets of 74 patients from multicenter Merck and American College of Radiology Imaging Network

13 est datasets of 74 patients from multicenter Merck and American College of Radiology Imaging Network

14 Merck and Co, National Institutes of Health.

15 rch by laboratories in the nonprofit sector, Merck and GlaxoSmithKline are developing commercial vers

16 -type (Dumas) or vaccine VZV strains ((POka, Merck and GSK).

17 of ADK inhibitors that have been reported by Merck and Shionogi pharmaceutical companies, served as m

18 e of licensed zoster vaccine (ZV) (Zostavax; Merck) and followed for occurrence of HZ for >/=1 year (

19 lyT1 inhibitors ALX-5407 (Allelix), (S)-13h (Merck), and SSR504734 (Sanofi-Synthelabo) were similar a

20 nstitute of Allergy and Infectious Diseases, Merck, and South African Medical Research Council.

21 uated vaccines for gastroenteritis (Rotateq [Merck] and Rotarix) have been licensed in many countries

22 through CD11b/CD18 were strongly blocked by Merck C, an imidazole-based inhibitor of p38 mitogen-act

23 f p38 MAPK, but not ERK1/2, was inhibited by Merck C.

24 tional Heart, Lung, and Blood Institute; and Merck Childhood Asthma Network sponsored a joint worksho

25 ilent Zorbax SB300, Waters Symmetry 300, and Merck Chromolith.

26 of Haemophilus influenzae type B vaccines by Merck & Co Inc, Whitehouse Station, New Jersey, USA, the

27 Merck Sharpe & Dohme-Merck & Co, Canadian Cancer Society, Swiss Cancer League

28 ng litigation related to rofecoxib involving Merck & Co, including internal company analyses and info

29 ingual immunotherapy (SLIT) tablet (MK-8237; Merck & Co, Kenilworth, NJ/ALK-Abello, Horsholm, Denmark

30 orking industrial scientists for 15 years at Merck & Co. and by similarly characterized students, pos

31 Merck & Co. and the National Heart, Lung, and Blood Inst

32 stribution of ivermectin - a drug donated by Merck & Co. for disease control in Africa and for diseas

33 measured, physiological effect of Claritin (Merck & Co.), a leading antihistamine medication, across

34 chnology from DiscoveRx to screen the entire Merck compound library for glucocorticoid receptor (GR)

35 tion of human liver P450 3A4 by L-754,394, a Merck compound synthesized as a potential HIV protease i

36 tionship studies of compounds related to the Merck cyclic hexapeptide c[Pro6-Phe7-d-Trp8-Lys9-Thr10-P

37 rono SA-Geneva, Switzerland; an affiliate of Merck, Darmstadt, Germany.

38 In 1989, Larsen et al. at Merck discovered that the addition of chiral alcohols to

39 ccines (RV1 [Rotarix; GSK] and RV5 [RotaTeq; Merck]) diverge.

40 ical trials, documents were found describing Merck employees working either independently or in colla

41 nalysis of >1000 ESTs generated by the WashU-Merck EST project.

42 irus type 5 (Ad5)-based vaccine developed by Merck failed to either prevent HIV-1 infection or suppre

43 3 reports worldwide voluntarily submitted to Merck, for an overall reporting rate of 3.4 reports/10,0

44 Varivax is described using data submitted to Merck from routine global postmarketing surveillance, co

45 thacin or selective inhibition of COX-2 with Merck Frosst (MF) tricyclic, retards significantly ather

46 one of the most potent DKAs reported by the Merck group (L-708,906) and found that 5CITEP inhibits 3

47 Varicella vaccine (Varivax, Merck) has been available in the United States since 199

48 ccines being prepared by GlaxoSmithKline and Merck have completed large-scale clinical trials.

49 collection, analysis, and dissemination; and Merck hid the marketing nature of the trial from partici

50 V protease, monofluorinated analogues of the Merck HIV protease inhibitor indinavir, are described.

51 se of licensed zoster vaccine (ZV; Zostavax; Merck) in 50-59-year-olds showed approximately 70% vacci

52 vine reassortant rotavirus vaccine (RotaTeq; Merck) in developed countries have demonstrated that it

53 n antibiotic drug Cefoxitin sodium (Mefoxin; Merck Inc., West Point, PA) with high efficacy.

54 es assembled from common sources such as the Merck Index, pesticide and pharmaceutical compilations,

55 The NK-1R antagonist aprepitant (Emend, Merck) inhibited both the SP-induced Ca2+ increase in PM

56 ialization, Codexis and Schering-Plough (now Merck) jointly developed a chemoenzymatic asymmetric syn

57 Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).

58 Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).

59 rancophone de Cancerologie Digestive (FFCD), Merck KGaA, and Sanofi-Aventis.

60 Merck Serono SA Geneva, a subsidiary of Merck KGaA, Darmstadt, Germany.

61 Research Wales, UK Medical Research Council, Merck KGgA.

62 rate was also significantly enhanced by both Merck L7 alone and TLK16998 plus insulin.

63 Both TLK16998 and Merck L7 improved IR autophosphorylation in cells with d

64 bol acetate)-treated cells, TLK16998 but not Merck L7 was able to significantly reverse the impaired

65 (IR) beta-subunit tyrosine kinase activity: Merck L7, a direct IR agonist, and Telik's TLK16998, an

66 ilead Sciences, Janssen Pharmaceuticals, and Merck Laboratories.

67 S, Gilead Sciences, Janssen Pharmaceuticals, Merck Laboratories.

68 Merck, Leukemia and Lymphoma Society, National Institute

69 Harrison's Textbook of Medicine, The Merck Manual, and Scientific American Medicine often men

70 view papers, documents were found describing Merck marketing employees developing plans for manuscrip

71 Varivax (varicella virus vaccine live [Oka/Merck]; Merck), a live attenuated varicella vaccine, is

72 34 from the ACRIN 6678 trial and 40 from the Merck MK-0646-008 trial).

73 lar mechanics calculation approach using the Merck Molecular Force Field (MMFFs) was developed; this

74 mice with vehicle or with a GSI developed by Merck (MRK-003).

75 TLC determinations were similarly made using Merck NH2 F254S precoated glass plates (approximately 2

76 conversion rates, before and after 1 dose of Merck/Oka varicella vaccine.

77 y, Phenomenex, Hypersil, and Chromolith from Merck; one polymeric bonded phase, Vydac) with the same

78 rs Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmace

79 We report composite results from the Merck phase I program of near-consensus clade B human im

80 columns (from Akzo Nobel, Bishoff, Hypersil, Merck, Phenomenex, Supelco, Vydac, and Waters) with seve

81 ths with: 1) vehicle; 2) AT(1)-ant (L158809, Merck, Rahway, New Jersey); 3) AT(1)-ant + AT(2)-ant (PD

82 5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study re

83 in support of a drug development program at Merck Research Laboratories.

84 a potent, highly selective CCR5 antagonist, Merck's compound 167 (CMPD 167), in an established cynom

85 cal trial articles published a disclosure of Merck's financial support, but only 50% (36 of 72) of re

86 of equations were derived and implemented on Merck's intranet to score single sensorgrams to distingu

87 g division to fulfill a marketing objective; Merck's marketing division handled both the scientific a

88 aled 3 key themes: The trial was designed by Merck's marketing division to fulfill a marketing object

89 t ADVANTAGE was a seeding trial developed by Merck's marketing division to promote prescription of Vi

90 The key structural feature in Boceprevir, Merck's new drug treatment for hepatitis C, is the bicyc

91 However, Merck's nonavalent vaccine, produced via the Saccharomyc

92 Results from Merck's phase II adenovirus type 5 (Ad5) gag/pol/nef tes

93 Merck's Raltegravir (RAL) (October 2007) and Gilead's El

94 ole (3) was identified from screening of the Merck sample collection as a human dopamine D4 (hD4) rec

95 versions, including (1) cortisone/cortisol (Merck/Sarett), (2) dendrobine (Kende), (3) vitamin B(12)

96 Merck/Schering-Plough Pharmaceuticals; Australian Nation

97 Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).

98 Merck Serono SA Geneva, a subsidiary of Merck KGaA, Darm

99 Merck Serono SA-Geneva, Switzerland; an affiliate of Mer

100 Scotland, and Northern Ireland, Biogen Idec, Merck Serono, Bayer Schering Pharmaceuticals, Teva Pharm

101 ional HbA1c Surveillance System [CNHSS]) and Merck Sharp & Dohme China (for the 3B study).

102 Oncoethix GmbH (a wholly owned subsidiary of Merck Sharp & Dohme Corp).

103 Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.

104 bVie, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme, ViiV Italy.

105 US National Cancer Institute, Merck Sharp & Dohme.

106 Merck Sharpe & Dohme-Merck & Co, Canadian Cancer Society

107 A rigorous analysis of the Merck-sponsored EST data with respect to known gene sequ

108 ew articles published either a disclosure of Merck sponsorship or a disclosure of whether the author

109 The Merck STEP phase 2b efficacy trial of one such vaccine w

110 cts vaccinated with Ad5-HIV-1 vectors in the Merck STEP trial remain unclear.

111 alyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveilla

112 Merck; The Clinical Trial Service Unit also receives fun

113 The corresponding RCs from the Merck trial were -35% (95% CI, -42% to -29%) and +53% (9

114 or the ACRIN trial and 6.89 +/- 3.02 for the Merck trial.

115 parison group for HPV-16 (2393 vs 3892 milli-Merck units per milliliter [mMU/mL], P = .012) and HPV-1

116 er last vaccination for HPV-16 of 7736 milli-Merck units per mL (mMU/mL) (95% CI, 6651-8999) and HPV-

117 (geometric mean antibody titer = 53.9 milli-Merck units/ml, 95% CI, 34.8 to 83.7).

118 The Merck vaccine also targets HPV6 and HPV11, which account

119 n Mexico and the Dominican Republic, and the Merck vaccine could be licensed in the United States wit

120 After US licensure of the Merck varicella vaccine for immunocompetent persons on 1

121 The Oka/Merck varicella vaccine induces VZV immunity in elderly

122 ut the immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (h

123 ficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine.

124 ous Diseases, Boehringer Ingelheim, Janssen, Merck, ViiV Healthcare, Roche, and Monogram Biosciences

125 al of an investigational live attenuated Oka/Merck VZV vaccine ("zoster vaccine").

126 The Pregnancy Registry for Varivax (Merck) was established to monitor for congenital varicel

127 ion of expressed sequence tags (ESTs) by the Merck/WashU EST project.

128 e-activated receptor-1 antagonist vorapaxar (Merck, Whitehouse Station, New Jersey) versus placebo am

129 he SP receptor antagonist aprepitant (Emend; Merck, Whitehouse Station, NJ) completely reversed the i

130 scrutiny because long-term rofecoxib (Vioxx; Merck, Whitehouse Station, NJ) treatment was found to in

131 lysin toxoid (psiPLY), Pneumovax 23 (PPSV23; Merck, Whitehouse Station, NJ), or phosphate-buffered sa